Culture
September 13, 2021

LARVOL Expands Commitment to Virtual Reality Workspace for Global Team

Culture
April 28, 2021

LARVOL Expands Commitment to Virtual Reality Workspace for Global Team

Author

Headset distribution solidifies intent to remain #1 VR-first company

San Francisco, CA (April 28, 2021) –  LARVOL, leading provider of data and intelligence solutions for the pharmaceutical and biotech industry, today announced their commitment to rollout virtual reality headsets to all team members in support of their Virtual Reality (VR)-first company culture. This gives all members of LARVOL’s global, remote workforce access to the company’s virtual reality office space and confirms the brand’s commitment to VR as the future of work.

“We have experienced firsthand the benefits of doing business in VR, and there’s no going back,” said CEO and Founder Bruno Larvol. “We are officially the first colony on the metaverse, and it is great to feel like we’re finally working together under one roof.”

A remote-first company since 2004, LARVOL is no stranger to the realities of a distributed work force. With teammates in 14 countries, the need to establish and grow a connected company culture is crucial to LARVOL’s success. In the past year, CEO Bruno Larvol embraced VR meetings as an opportunity to enhance the connection and collaboration for the team. Extensive testing of Oculus Quest 2 headsets and the Spatial VR office application convinced the CEO that VR gatherings present a significant improvement to meeting via video alone, better mimicking the environment of an in-person gathering.

“We found the office space we never thought we needed in VR with Spatial’s collaboration platform,” Larvol said. “We are collaborating more fully and connecting on a human level that video conferencing has never allowed. This flexibility has also allowed us to hire the best talent and give our staff the flexibility today’s workforce is looking for.”

LARVOL announced the rollout of an Oculus Quest 2 headset to every team member’s home office at an All Hands meeting held in Spatial this morning. Team members from across the globe will now be able to enjoy the immersive VR experience that makes LARVOL a pioneer in VR-first business.

For more information visit LARVOL.com.

About LARVOL:

LARVOL supports the data and intelligence needs of the pharmaceutical and biotech industry with expert curated information. Their products include competitive intelligence, KOL monitoring, and social listening tools along with predictive cancer biomarker and clinical trial databases. LARVOL curates data using a proven combination of broad therapeutic-area expertise and proprietary natural language processing technology to keep their customers at the forefront of the industry. The VR-first, remote-always LARVOL team includes MDs, PhDs, and industry professionals around the globe who curate data from over 25,000 sources and distill the most relevant information into concise reports that provide real-time insights and time-saving analysis.

About Spatial:

Spatial is pioneering the next generation of collaborative 3D computing- offering entirely new way to collaborate through Augmented Reality (AR) and Virtual Reality (VR) workspaces. It transforms your room into your monitor, allowing rich, interactive 3D exploration that would be impossible in the physical world. In the process, teams grow closer, think bigger, and accomplish things faster.

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.